{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:49:59Z","timestamp":1776703799144,"version":"3.51.2"},"reference-count":19,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2015,6,22]]},"abstract":"<jats:p>We present a case of a patient with a diagnostic dilemma who was referred for possible faecal microbiota transplantation (FMT) for refractory diarrhoea secondary to <jats:italic>Clostridium difficile<\/jats:italic> infection (CDI). On detailed history, the patient was exposed to ipilimumab concomitantly while being treated for CDI, and was instead diagnosed with diarrhoea secondary to superimposed ipilimumab-associated colitis. Ipilimumab is an anti-CTLA4 monoclonal antibody approved for use in metastatic melanoma and under trial for other indications. Ipilimumab is associated with several immune-related adverse effects, of which diarrhoea and colitis are the most common. While FMT has shown tremendous efficacy in managing recurrent and refractory CDI, it was not offered in this case due to negative <jats:italic>C. difficile<\/jats:italic> testing showing a high degree of suspicion for ipilimumab-associated colitis due to recent drug use. Our patient was successfully managed with fluid resuscitation and steroids, and remains symptom free at last follow-up at 9\u2005months.<\/jats:p>","DOI":"10.1136\/bcr-2015-211160","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T04:09:03Z","timestamp":1436242143000},"page":"bcr2015211160","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Ipilimumab-associated colitis or refractory <i>Clostridium difficile<\/i> infection?"],"prefix":"10.1136","volume":"2015","author":[{"given":"Arjun","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.2","first-page":"63","article-title":"Community-acquired Clostridium difficile infection: an increasing public health threat","volume":"7","author":"Gupta","year":"2014","journal-title":"Infect Drug Resist"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.07.012"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir632"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.7","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13508519"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.8","doi-asserted-by":"crossref","unstructured":"De Felice KM , Gupta A , Rakshit S , et al . Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015.","DOI":"10.1097\/CMR.0000000000000165"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.9","doi-asserted-by":"crossref","unstructured":"Gupta A , De Felice KM , Loftus Jr EV , et al . Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; in press.","DOI":"10.1111\/apt.13281"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.10","doi-asserted-by":"publisher","DOI":"10.1586\/egh.10.48"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.11","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.95"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.245"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2468"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.15","first-page":"28","article-title":"Infectious colitis associated with ipilimumab therapy","volume":"7","author":"McCutcheon","year":"2014","journal-title":"Gastroenterol Res"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health. National Cancer Institute [cited 28 May 2009 (v4.03: 14 June, 2010)]. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5\u00d711.pdf"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.17","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0641-z"},{"key":"2025082804074136000_2015.jul07_1.bcr2015211160.19","first-page":"934","article-title":"Ipilimumab induced enterocolitis: a fatal immune-related adverse event of melanoma treatment","volume":"2","author":"Babi","year":"2013","journal-title":"J Gastroenterol Hepatol Res"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-211160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:07:51Z","timestamp":1756379271000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-211160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":19,"alternative-id":["10.1136\/bcr-2015-211160"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-211160","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]}}}